# A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

> **NCT02655614** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 54 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** GDC-0134
- **DRUG:** Placebo
- **DRUG:** Rabeprazole
- **DRUG:** Midazolam
- **DRUG:** Caffeine

## Key facts

- **NCT ID:** NCT02655614
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-31
- **Primary completion:** 2020-03-16
- **Final completion:** 2020-03-16
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2020-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02655614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02655614, "A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02655614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*